Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer

详细信息    查看全文

• 作者：Grace L. Lu-Yao^a ; ^b ; ^{luyaogr@cinj.rutgers.edu" class="auth_mail" title="E-mail the corresponding author} ; Peter C. Albertsen^c ; Dirk F. Moore^a ; ^d ; Yong Lin^a ; ^d ; Robert S. DiPaola^a ; ^b ; Siu-Long Yao^a ; ^b
• 关键词：Prostatic neoplasm ; Survival ; Population-based study
• 刊名：European Urology
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：68
• 期：5
• 页码：805-811
• 全文大小：1977 K

文摘

To understand the threat posed by localized prostate cancer and the potential impact of surgery or radiation, patients and healthcare providers require information on long-term outcomes following conservative management.

Objective

To describe 15-yr survival outcomes and cancer therapy utilization among men 65 years and older managed conservatively for newly diagnosed localized prostate cancer.

Design, settings, and participants

This is a population-based cohort study with participants living in predefined geographic areas covered by the Surveillance, Epidemiology, and End Results program. The study includes 31 137 Medicare patients aged ≥65 yr diagnosed with localized prostate cancer in 1992–2009 who initially received conservative management (no surgery, radiotherapy, cryotherapy, or androgen deprivation therapy [ADT]). All patients were followed until death or December 31, 2009 (for prostate cancer–specific mortality [PCSM]) and December 31, 2011 (for overall mortality).

Outcome measurements and statistical analysis

Competing-risk analyses were used to examine PCSM, overall mortality, and utilization of cancer therapies.

Results and limitations

The 15-yr risk of PCSM for men aged 65–74 yr diagnosed with screening-detected prostate cancer was 5.7% (95% confidence interval [CI] 3.7–8.0%) for T1c Gleason 5–7 and 22% (95% CI 16–35%) for Gleason 8–10 disease. After 15 yr of follow-up, 24% (95% CI 21–27%) of men aged 65–74 yr with screening-detected Gleason 5–7 cancer received ADT. The corresponding result for men with Gleason 8–10 cancer was 38% (95% CI 32–44%). The major study limitations are the lack of data for men aged <65 yr and detailed clinical information associated with secondary cancer therapy.

Conclusions

The 15-yr outcomes following conservative management of newly diagnosed Gleason 5–7 prostate cancer among men aged ≥65 yr are excellent. Men with Gleason 8–10 disease managed conservatively face a significant risk of PCSM.

Patient summary

We examined the long-term survival outcomes for a large group of patients diagnosed with localized prostate cancer who did not have surgery, radiotherapy, cryotherapy, or androgen deprivation therapy in the first 6 mo after cancer diagnosis. We found that the 15-yr disease-specific survival is excellent for men diagnosed with Gleason 5–7 disease. The data support conservative management as a reasonable choice for elderly patients with low-grade localized prostate cancer.